Related Experiment Videos
[Cyclosporine in inflammatory bowel disease]
J Colomina Avilés1, R Pascual Pérez, J Ortuño Cortés
1Servicio de Medicina Interna, Hospital General de Elda, Alicante.
Anales De Medicina Interna (Madrid, Spain : 1984)
|June 3, 1998
Summary
Cyclosporine A (CYA) shows promise for severe Inflammatory Bowel Disease (IBD) cases resistant to steroids, potentially avoiding surgery. Further controlled trials are needed to define its role and manage potential toxicity.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Context:
- Inflammatory Bowel Disease (IBD), encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD), presents challenges with steroid-resistant severe outbreaks.
- Current treatments for refractory IBD include surgery or immunosuppressants like mercaptopurine or azathioprine.
Purpose:
- To evaluate the efficacy and role of Cyclosporine A (CYA) in managing severe, treatment-resistant Inflammatory Bowel Disease (IBD).
- To assess CYA's potential in avoiding colectomy for severe Ulcerative Colitis (UC) and healing fistulas in Crohn's Disease (CD).
Summary:
- Cyclosporine A (CYA) is a selective T-helper lymphocyte immunosuppressor, not a first-line IBD therapy.
- Limited controlled trials exist, but one showed CYA superior to placebo in UC, avoiding colectomy in one-third of severe cases.
- CYA may aid in healing refractory Crohn's Disease (CD) fistulas.
Impact:
- CYA's potential toxicity and limited controlled data necessitate further research to establish its definitive role in IBD treatment.
- Additional controlled trials are required to clarify the therapeutic positioning of CYA for severe IBD.
- Understanding CYA's benefits and risks is crucial for optimizing management strategies in steroid-refractory IBD.